ArticleCell cycle (Georgetown, Tex.)2022

STING agonist enhances the efficacy of programmed death-ligand 1 monoclonal antibody in breast cancer immunotherapy by activating the interferon-β signalling pathway.

Mingming Yin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.